Recombinant Human PSMA7 Protein, N-His from ProteoGenix; catalogue ARO-P12212; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Introduction
Recombinant Human PSMA7 Protein, also known as Proteasome subunit alpha type-7, is a protein that plays a crucial role in the cellular degradation process. This protein is encoded by the PSMA7 gene and is a part of the proteasome complex, which is responsible for breaking down and recycling damaged or unwanted proteins in the cell. In this article, we will discuss the structure, activity, and applications of Recombinant Human PSMA7 Protein.
Structure of Recombinant Human PSMA7 Protein
Recombinant Human PSMA7 Protein is a 246 amino acid long protein with a molecular weight of approximately 28 kDa. It is composed of two subunits, alpha and beta, which are arranged in a cylindrical shape to form the 20S proteasome core particle. The alpha subunits, including PSMA7, are responsible for the catalytic activity of the proteasome, while the beta subunits act as structural support.
The primary structure of Recombinant Human PSMA7 Protein consists of a conserved N-terminal threonine residue, which is essential for its catalytic activity. The protein also contains several lysine and arginine residues, which are important for its interaction with other proteins. The C-terminal region of PSMA7 contains a proteasome-activating nucleotide-binding domain, which is involved in the regulation of proteasome activity.
Activity of Recombinant Human PSMA7 Protein
Recombinant Human PSMA7 Protein is a key component of the proteasome complex, which is responsible for the degradation of misfolded or damaged proteins in the cell. It acts as a peptidase, which cleaves proteins into smaller peptides that can be further broken down into amino acids and recycled by the cell.
The catalytic activity of Recombinant Human PSMA7 Protein is regulated by the binding of ATP and other regulatory proteins. It has been shown to have a preference for cleaving proteins with hydrophobic or basic amino acid residues. This activity is essential for maintaining cellular homeostasis and preventing the accumulation of toxic proteins.
Applications of Recombinant Human PSMA7 Protein
1. Research Tool: Recombinant Human PSMA7 Protein is widely used as a research tool in various cellular and molecular biology studies. It can be used to study the function and regulation of the proteasome complex, as well as its role in diseases such as cancer and neurodegenerative disorders.
2. Therapeutic Target: Dysregulation of the proteasome complex has been linked to various diseases, making it a potential therapeutic target. Recombinant Human PSMA7 Protein can be used to screen and develop inhibitors or activators of the proteasome, which can be used to treat these diseases.
3. Diagnostic Marker: The expression of PSMA7 has been found to be altered in several types of cancer, making it a potential diagnostic marker. Recombinant Human PSMA7 Protein can be used to develop diagnostic tests to detect the presence of cancer cells in patient samples.
4. Vaccine Development: Recombinant Human PSMA7 Protein has been identified as an antigen in prostate cancer cells. It can be used to develop vaccines that target this specific antigen, providing a more targeted and effective treatment option for prostate cancer patients.
Conclusion
Recombinant Human PSMA7 Protein is a crucial component of the proteasome complex, responsible for the degradation of unwanted or damaged proteins in the cell. Its structure and catalytic activity make it an important research tool, therapeutic target, diagnostic marker, and potential vaccine candidate. Further studies on this protein can provide valuable insights into its role in cellular processes and its potential applications in disease treatment.
ProteoGenix catalogue number ARO-P12212. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 28.64 kDa; Fragment: His15-Ser248; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
